Form 4: Nuvation Bio CEO David Hung Increases Stake in Company with $837,000 Stock Purchase

Nuvation Bio's CEO, David Hung, recently acquired 500,000 shares of Class A Common Stock, signaling a strong commitment to the company's future.

Summary

• David Hung, the CEO of Nuvation Bio Inc., has increased his holdings in the company by purchasing 500,000 shares of Class A Common Stock.
• The purchases were made in two transactions on April 4, 2025, and April 7, 2025.
• On April 4, 2025, Mr. Hung bought 200,000 shares at a weighted-average price of $1.6636, with individual prices ranging from $1.6499 to $1.6699.
• On April 7, 2025, he acquired an additional 300,000 shares at a weighted-average price of $1.625, with individual prices ranging from $1.54 to $1.78.
• Following these transactions, Mr. Hung directly owns 58,781,054 shares of Nuvation Bio's Class A Common Stock.
• A Power of Attorney document was also filed, authorizing Stephen Dang, Moses Makunje, and Philippe Sauvage to act on behalf of David Hung in matters related to SEC filings.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's significant stock purchase, indicating confidence in the company. However, it's a routine filing, so the impact is limited.

Positives

• The CEO's purchase of a significant number of shares can be seen as a positive signal, indicating confidence in the company's prospects.
• Increased insider ownership aligns management's interests with those of other shareholders.
• The Power of Attorney ensures smooth and timely compliance with SEC reporting requirements.

Industry Context

Insider buying is often viewed as a positive sign in the biotech industry, as it suggests that a company's leadership believes the company is undervalued and has strong growth potential. It is common for CEOs to hold significant equity positions in their companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Comparing David Hung's purchase to similar insider transactions in comparable biotech companies would require further research into recent Form 4 filings of peer companies.
• A typical comparison would involve looking at the percentage of outstanding shares purchased by the CEO relative to the company's market capitalization and comparing that to similar transactions in companies like BeiGene, BioNTech, or Moderna.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase positively, potentially leading to increased investor confidence.
• Employees may see the CEO's investment as a sign of stability and commitment to the company's future.

Key Dates

Keywords

Nuvation Bio, David Hung, insider trading, stock purchase, Form 4, SEC, Class A Common Stock, ownership, Power of Attorney